PGP and neoplasm: However, efforts to reduce drug resistance using Pgp inhibitors have had limited efficacy due to their clinical toxicity from their broad substrate specificity, pharmacokinetic interactions with other drug transporters and enzymes, and constitutive expressions in both healthy and tumor cells [31].